Corporate
Biotrial introduces its entity BIOTRIAL ONCOLOGY
For over 35 years, Biotrial has been an innovative player in the field, both in Preclinical and Clinical studies. In response to evolving needs, Biotrial has decided to launch its new entity Biotrial Oncology.
For over 35 years, Biotrial has been an innovative player in the field, both in Preclinical and Clinical studies (in vitro and in vivo). To support our clients in their research, Biotrial relies on its experience as a global provider, internationally recognized experts, and an extensive network of specialized sites. In response to evolving needs, Biotrial has decided to launch its new entity Biotrial Oncology.
Our capabilities include:
- Translational expertise, ranging from preclinical to clinical, supported by the services of a human-sized global provider.
- A team of experienced professionals specialized in the latest designs and evaluation criteria in oncology.
- A commitment to excellence in research, fueled by close collaboration with sponsors developing innovative drugs.
- A team of leading KOLs and reference specialists.
- A network of specialized hospital centers allowing access to patients.
- International expertise in regulatory affairs and pharmacovigilance.
- A patient-centered approach.
“Biotrial Oncology aims to be the reference partner for early development of molecules in oncology, through its ability to offer innovative and customized solutions, as well as connecting all research players from chemists to patients.”
